Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) fell 0.5% on Wednesday . The stock traded as low as $22.52 and last traded at $23.00. 680,963 shares traded hands during trading, a decline of 83% from the average session volume of 4,001,895 shares. The stock had previously closed at $23.11.
Analyst Ratings Changes
VKTX has been the topic of several recent analyst reports. Scotiabank assumed coverage on shares of Viking Therapeutics in a research note on Thursday, February 13th. They set a "sector outperform" rating and a $102.00 target price on the stock. Maxim Group reduced their price objective on Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, February 7th. B. Riley reiterated a "buy" rating and issued a $96.00 target price (down previously from $109.00) on shares of Viking Therapeutics in a report on Friday, February 7th. Piper Sandler decreased their price target on shares of Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating for the company in a report on Thursday, February 6th. Finally, The Goldman Sachs Group assumed coverage on shares of Viking Therapeutics in a research report on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Viking Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $89.75.
Check Out Our Latest Research Report on VKTX
Viking Therapeutics Trading Up 1.4 %
The business's fifty day moving average price is $26.94 and its 200 day moving average price is $41.85. The company has a market capitalization of $2.69 billion, a P/E ratio of -23.94 and a beta of 0.84.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter in the prior year, the business posted ($0.25) EPS. Equities research analysts anticipate that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.
Insider Buying and Selling
In other Viking Therapeutics news, Director Sarah Kathryn Rouan acquired 1,240 shares of Viking Therapeutics stock in a transaction on Monday, March 31st. The shares were bought at an average price of $24.15 per share, with a total value of $29,946.00. Following the completion of the purchase, the director now owns 1,240 shares in the company, valued at $29,946. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.70% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in VKTX. Blue Trust Inc. increased its position in Viking Therapeutics by 75.9% in the 4th quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 309 shares in the last quarter. YANKCOM Partnership bought a new stake in shares of Viking Therapeutics during the fourth quarter valued at approximately $33,000. Parallel Advisors LLC increased its holdings in shares of Viking Therapeutics by 64.8% in the first quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 536 shares in the last quarter. FIL Ltd raised its position in Viking Therapeutics by 116.8% in the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 648 shares during the last quarter. Finally, NBC Securities Inc. lifted its holdings in Viking Therapeutics by 222,100.0% during the 1st quarter. NBC Securities Inc. now owns 2,222 shares of the biotechnology company's stock worth $53,000 after buying an additional 2,221 shares in the last quarter. 76.03% of the stock is owned by institutional investors.
About Viking Therapeutics
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Further Reading
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
